{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T04:11:52Z","timestamp":1783656712664,"version":"3.55.0"},"reference-count":68,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Substance Abuse"],"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:p>US health care systems are struggling to formulate quality metrics that are patient-centered and describe outcomes rather than processes. Addiction medicine is no exception. Of particular interest is the identification of quality metrics in opioid use disorder (OUD) treatment. The prevalence and lethality of OUD, together with concomitant efforts to increase provision of its care, makes well-designed and validated quality metrics especially important. One insightful approach has been to use the \u201ccascade of care\u201d model derived from human immunodeficiency virus\/acquired immunodeficiency syndrome (HIV\/AIDS) care. A core part of the cascade is \u201cretention in care,\u201d a concept initially identified during the development of methadone-based OUD care. Not only is retention in care associated with improved morbidity and mortality, it also offers strategic approaches to improving care for OUD. This paper provides an introduction to retention in care and its implications for quality measurement.<\/jats:p>","DOI":"10.1080\/08897077.2019.1635969","type":"journal-article","created":{"date-parts":[[2019,7,30]],"date-time":"2019-07-30T15:45:41Z","timestamp":1564501541000},"page":"453-458","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":15,"title":["Retention in Care as a Quality Measure for Opioid use Disorder"],"prefix":"10.1177","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0356-5440","authenticated-orcid":false,"given":"Stephen A.","family":"Martin","sequence":"first","affiliation":[{"name":"Department of Family Medicine and Community Health, University of Massachusetts Medical School and Barre Family Health Center, Barre, Massachusetts, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Chiodo","sequence":"additional","affiliation":[{"name":"College of Nursing, University of Massachusetts Amherst, Amherst, Massachusetts, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Wilson","sequence":"additional","affiliation":[{"name":"Addiction Research and Education Foundation, Florence, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2019,10,1]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2010.0575"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.13.1689"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2010.03140.x"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2016.16070792"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1370\/afm.2098"},{"key":"e_1_3_4_7_2","unstructured":"Alderks CE. Trends in the Use of Methadone Buprenorphine and Extended-release Naltrexone at Substance Abuse Treatment Facilities: 2003-2015 (Update). https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/report_3192\/ShortReport-3192.html. Published August 22 2017. Accessed August 29 2018."},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2015.302664"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.7326\/M17-3107"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000210"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g5432"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.0029"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001902"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2018.03.001"},{"key":"e_1_3_4_15_2","unstructured":"Substance Abuse and Mental Health Services Administration. Finding Quality Treatment for Substance Use Disorders. https:\/\/store.samhsa.gov\/product\/PEP18-TREATMENT-LOC. Published April 2018. Accessed February 19 2018."},{"key":"e_1_3_4_16_2","doi-asserted-by":"crossref","unstructured":"Kaplan S. F.D.A. to expand medication-assisted therapy for opioid addicts. The New York Times. February 26 2018:A10.","DOI":"10.1097\/00006205-900000000-99727"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.17226\/23589"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j373"},{"key":"e_1_3_4_19_2","unstructured":"Roscoe C Hachey DM. Core Concepts: Retention in HIV Care. Natl HIV Curric. https:\/\/www.hiv.uw.edu\/go\/basic-primary-care\/retention-care\/core-concept\/all. Published May 13 2017. Accessed February 17 2018."},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.920"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1086\/649933"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1086\/516778"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(59)90169-9"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1080\/09540120220149948"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/add.13479"},{"key":"e_1_3_4_26_2","unstructured":"Overview|HIV.gov. https:\/\/www.hiv.gov\/federal-response\/national-hiv-aids-strategy\/overview. Published January 31 2017. Accessed October 8 2018."},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2010.0086"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1525-1497.1999.00322.x"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.3356"},{"key":"e_1_3_4_30_2","unstructured":"Williams AR Nunes E Olfson M. To battle the opioid overdose epidemic deploy the \u2018cascade of care\u2019 model. Heal Aff Blog. https:\/\/www.healthaffairs.org\/do\/10.1377\/hblog20170313.059163\/full\/. Published March 13 2017."},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2018.06.001"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1965.03090080008002"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-011711-113247"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.58.5.503"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000312"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1097\/HRP.0000000000000052"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2018.05.010"},{"key":"e_1_3_4_38_2","unstructured":"Substance Abuse and Mental Health Services Administration. TIP 63: Medications for Opioid Use Disorders \u2013 Full Document (Including Executive Summary and Parts 1-5). https:\/\/store.samhsa.gov\/product\/SMA18-5063FULLDOC. Published 2018. Accessed February 22 2018."},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1802741"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c5475"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j1550"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1080\/10550887.2016.1100960"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2016.12.010"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/add.13270"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1177\/1060028017751913"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2014.5416"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1002\/syn.890110303"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1604223"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2017.09.017"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13722-017-0072-2"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2013.10.004"},{"key":"e_1_3_4_52_2","unstructured":"PROMIS: Patient-Reported Outcomes Measurement Information System. http:\/\/www.healthmeasures.net\/explore-measurement-systems\/promis. Accessed March 17 2018."},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1611252"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.7326\/M18-1652"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1521-0391.2013.12032.x"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000406"},{"key":"e_1_3_4_57_2","unstructured":"American Society of Addiction Medicine. National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use. http:\/\/www.asam.org\/quality-practice\/guidelines-and-consensus-documents\/npg\/complete-guideline. Published June 1 2015. Accessed February 25 2018."},{"key":"e_1_3_4_58_2","unstructured":"Center for Drug Evaluation and Research. FDA Drug Safety Communication: FDA urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: careful medication management can reduce risks. https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm575307.htm. Published September 20 2017. Accessed November 30 2017."},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13722-017-0092-y"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1111\/add.12333"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1111\/ajad.12414"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ps.201700363"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1111\/ajad.12288"},{"key":"e_1_3_4_64_2","doi-asserted-by":"publisher","DOI":"10.9740\/mhc.2017.11.271"},{"key":"e_1_3_4_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2015.04.002"},{"key":"e_1_3_4_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2017.05.010"},{"key":"e_1_3_4_67_2","unstructured":"Drago J. Buprenorphine Treatment for Opioid Addiction in the Primary Care Setting: Predictors of Treatment Success and Failure. https:\/\/dash.harvard.edu\/handle\/1\/17295887. Published 2015. Accessed July 13 2017."},{"key":"e_1_3_4_68_2","doi-asserted-by":"publisher","DOI":"10.1111\/ajad.12553"},{"key":"e_1_3_4_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2017.05.010"}],"container-title":["Substance Abuse"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1080\/08897077.2019.1635969","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1080\/08897077.2019.1635969","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1080\/08897077.2019.1635969","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T12:45:19Z","timestamp":1780490719000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1080\/08897077.2019.1635969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":68,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["10.1080\/08897077.2019.1635969"],"URL":"https:\/\/doi.org\/10.1080\/08897077.2019.1635969","relation":{},"ISSN":["0889-7077","1547-0164"],"issn-type":[{"value":"0889-7077","type":"print"},{"value":"1547-0164","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10]]}}}